Browsing category:

Antispasticity Agent


The January 6, 2015 issue of Cell Metabolism offered exciting news regarding the fight against obesity. Mirabegron, an FDA approved drug for treating overactive bladder, appears to be a viable option for combatting obesity as well. The secret is in Mirabegron’s ability to metabolize brown fat, which generates heat by burning energy, which fights obesity.[…]

Read More

Canadian Patients got good news on April 10, 2013 when the availability of Mirabegron for OAB (Overactive Bladder) was announced. “Now that Myrbetriq is available through pharmacies, Canadian patients have access to the first new class of medication for the treatment of OAB in over 30 years,” said Michael Tremblay, President, Astellas Pharma Canada, Inc.  Astellas[…]

Read More

Oxybutynin Chloride is an antispasmodic and anticholinergic medication. Effective for the treatment of a variety of bladder conditions, such as overactive bladder, detrusor instability, detrusor hyperreflexia, spasmodic bladder, unstable bladder, irritable bladder, incontinence and bladder spasms, the brand name for this medication is Ditropan XL. Ortho-McNeil Pharmaceutical Inc. markets oxybutynin chloride as Ditropan XL, with[…]

Read More

Oxybutynin, CAS# 5633-20-5, is known as the brand name Oxytrol. Marketed by Watson, this medication used to treat overactive bladder has a patent expiration of Apr 26, 2015. As an industry standard used to treat the symptoms of overactive bladder, also known as OAB, oxybutynin has proven to be both efficacious and safe. As the[…]

Read More